Targeted therapy with MXD3 siRNA, anti-CD22 antibody and nanoparticles for precursor B-cell acute lymphoblastic leukaemia

Noriko Satake, Connie Duong, Cathy Chen, Gustavo Barisone, Elva D Diaz, Joseph Tuscano, David M Rocke, Jan Nolta, Nitin Nitin

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Summary: Conventional chemotherapy for precursor B-cell (preB) acute lymphoblastic leukaemia (ALL) has limitations that could be overcome by targeted therapy. Previously, we discovered a potential therapeutic molecular target, MDX3 (MAX dimerization protein 3), in preB ALL. In this study, we hypothesize that an effective siRNA therapy for preB ALL can be developed using antiCD22 antibody (αCD22 Ab) and nanoparticles. We composed nanocomplexes with super paramagnetic iron oxide nanoparticles (SPIO NPs), αCD22 Abs and MXD3 siRNA molecules based on physical interactions between the molecules. We demonstrated that the MXD3 siRNA-αCD22 Ab-SPIO NP complexes entered leukaemia cells and knocked down MXD3, leading the cells to undergo apoptosis and resulting in decreased live cell counts in the cell line Reh and in primary preB ALL samples in vitro. Furthermore, the cytotoxic effects of the MXD3 siRNA-αCD22 Ab-SPIO NP complexes were significantly enhanced by addition of the chemotherapy drugs vincristine or doxorubicin. We also ruled out potential cytotoxic effects of the MXD3 siRNA-αCD22 Ab-SPIO NP complexes on normal primary haematopoietic cells. Normal B cells were affected while CD34-positive haematopoietic stem cells and non-B cells were not. These data suggest that MXD3 siRNA-αCD22 Ab-SPIO NP complexes have the potential to be a new targeted therapy for preB ALL.

Original languageEnglish (US)
Pages (from-to)487-499
Number of pages13
JournalBritish Journal of Haematology
Volume167
Issue number4
DOIs
StatePublished - Nov 1 2014

Fingerprint

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Nanoparticles
Small Interfering RNA
Anti-Idiotypic Antibodies
Therapeutics
Protein Multimerization
Drug Therapy
Vincristine
Hematopoietic Stem Cells
Doxorubicin
Leukemia
B-Lymphocytes
Cell Count
ferric oxide
Apoptosis
Cell Line
Antibodies
Pharmaceutical Preparations

Keywords

  • AntiCD22 antibody
  • MXD3 siRNA
  • Precursor B-cell acute lymphoblastic leukaemia
  • RNA inhibition
  • Superparamagnetic iron oxide nanoparticle

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Targeted therapy with MXD3 siRNA, anti-CD22 antibody and nanoparticles for precursor B-cell acute lymphoblastic leukaemia. / Satake, Noriko; Duong, Connie; Chen, Cathy; Barisone, Gustavo; Diaz, Elva D; Tuscano, Joseph; Rocke, David M; Nolta, Jan; Nitin, Nitin.

In: British Journal of Haematology, Vol. 167, No. 4, 01.11.2014, p. 487-499.

Research output: Contribution to journalArticle

@article{57484d7854fd486c9ba461ec503c59da,
title = "Targeted therapy with MXD3 siRNA, anti-CD22 antibody and nanoparticles for precursor B-cell acute lymphoblastic leukaemia",
abstract = "Summary: Conventional chemotherapy for precursor B-cell (preB) acute lymphoblastic leukaemia (ALL) has limitations that could be overcome by targeted therapy. Previously, we discovered a potential therapeutic molecular target, MDX3 (MAX dimerization protein 3), in preB ALL. In this study, we hypothesize that an effective siRNA therapy for preB ALL can be developed using antiCD22 antibody (αCD22 Ab) and nanoparticles. We composed nanocomplexes with super paramagnetic iron oxide nanoparticles (SPIO NPs), αCD22 Abs and MXD3 siRNA molecules based on physical interactions between the molecules. We demonstrated that the MXD3 siRNA-αCD22 Ab-SPIO NP complexes entered leukaemia cells and knocked down MXD3, leading the cells to undergo apoptosis and resulting in decreased live cell counts in the cell line Reh and in primary preB ALL samples in vitro. Furthermore, the cytotoxic effects of the MXD3 siRNA-αCD22 Ab-SPIO NP complexes were significantly enhanced by addition of the chemotherapy drugs vincristine or doxorubicin. We also ruled out potential cytotoxic effects of the MXD3 siRNA-αCD22 Ab-SPIO NP complexes on normal primary haematopoietic cells. Normal B cells were affected while CD34-positive haematopoietic stem cells and non-B cells were not. These data suggest that MXD3 siRNA-αCD22 Ab-SPIO NP complexes have the potential to be a new targeted therapy for preB ALL.",
keywords = "AntiCD22 antibody, MXD3 siRNA, Precursor B-cell acute lymphoblastic leukaemia, RNA inhibition, Superparamagnetic iron oxide nanoparticle",
author = "Noriko Satake and Connie Duong and Cathy Chen and Gustavo Barisone and Diaz, {Elva D} and Joseph Tuscano and Rocke, {David M} and Jan Nolta and Nitin Nitin",
year = "2014",
month = "11",
day = "1",
doi = "10.1111/bjh.13066",
language = "English (US)",
volume = "167",
pages = "487--499",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Targeted therapy with MXD3 siRNA, anti-CD22 antibody and nanoparticles for precursor B-cell acute lymphoblastic leukaemia

AU - Satake, Noriko

AU - Duong, Connie

AU - Chen, Cathy

AU - Barisone, Gustavo

AU - Diaz, Elva D

AU - Tuscano, Joseph

AU - Rocke, David M

AU - Nolta, Jan

AU - Nitin, Nitin

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Summary: Conventional chemotherapy for precursor B-cell (preB) acute lymphoblastic leukaemia (ALL) has limitations that could be overcome by targeted therapy. Previously, we discovered a potential therapeutic molecular target, MDX3 (MAX dimerization protein 3), in preB ALL. In this study, we hypothesize that an effective siRNA therapy for preB ALL can be developed using antiCD22 antibody (αCD22 Ab) and nanoparticles. We composed nanocomplexes with super paramagnetic iron oxide nanoparticles (SPIO NPs), αCD22 Abs and MXD3 siRNA molecules based on physical interactions between the molecules. We demonstrated that the MXD3 siRNA-αCD22 Ab-SPIO NP complexes entered leukaemia cells and knocked down MXD3, leading the cells to undergo apoptosis and resulting in decreased live cell counts in the cell line Reh and in primary preB ALL samples in vitro. Furthermore, the cytotoxic effects of the MXD3 siRNA-αCD22 Ab-SPIO NP complexes were significantly enhanced by addition of the chemotherapy drugs vincristine or doxorubicin. We also ruled out potential cytotoxic effects of the MXD3 siRNA-αCD22 Ab-SPIO NP complexes on normal primary haematopoietic cells. Normal B cells were affected while CD34-positive haematopoietic stem cells and non-B cells were not. These data suggest that MXD3 siRNA-αCD22 Ab-SPIO NP complexes have the potential to be a new targeted therapy for preB ALL.

AB - Summary: Conventional chemotherapy for precursor B-cell (preB) acute lymphoblastic leukaemia (ALL) has limitations that could be overcome by targeted therapy. Previously, we discovered a potential therapeutic molecular target, MDX3 (MAX dimerization protein 3), in preB ALL. In this study, we hypothesize that an effective siRNA therapy for preB ALL can be developed using antiCD22 antibody (αCD22 Ab) and nanoparticles. We composed nanocomplexes with super paramagnetic iron oxide nanoparticles (SPIO NPs), αCD22 Abs and MXD3 siRNA molecules based on physical interactions between the molecules. We demonstrated that the MXD3 siRNA-αCD22 Ab-SPIO NP complexes entered leukaemia cells and knocked down MXD3, leading the cells to undergo apoptosis and resulting in decreased live cell counts in the cell line Reh and in primary preB ALL samples in vitro. Furthermore, the cytotoxic effects of the MXD3 siRNA-αCD22 Ab-SPIO NP complexes were significantly enhanced by addition of the chemotherapy drugs vincristine or doxorubicin. We also ruled out potential cytotoxic effects of the MXD3 siRNA-αCD22 Ab-SPIO NP complexes on normal primary haematopoietic cells. Normal B cells were affected while CD34-positive haematopoietic stem cells and non-B cells were not. These data suggest that MXD3 siRNA-αCD22 Ab-SPIO NP complexes have the potential to be a new targeted therapy for preB ALL.

KW - AntiCD22 antibody

KW - MXD3 siRNA

KW - Precursor B-cell acute lymphoblastic leukaemia

KW - RNA inhibition

KW - Superparamagnetic iron oxide nanoparticle

UR - http://www.scopus.com/inward/record.url?scp=84916196785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916196785&partnerID=8YFLogxK

U2 - 10.1111/bjh.13066

DO - 10.1111/bjh.13066

M3 - Article

C2 - 25196579

AN - SCOPUS:84916196785

VL - 167

SP - 487

EP - 499

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -